UroGen Pharma Ltd. (URGN)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

2Y 5Y 10Y All
Quarterly Annual TTM

Revenue Annual

0 40M 80M 120M FY16: 17.5M FY17: 8.2M FY18: 1.1M FY19: 18K FY20: 11.8M FY21: 48M FY22: 64.4M FY23: 82.7M FY24: 90.4M FY25: 109.8M FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Gross Profit Annual

-35M 0 35M 70M 105M FY16: 17.5M FY17: 7.6M FY18: -675K FY19: 18K FY20: 10.8M FY21: 42.9M FY22: 56.7M FY23: 73.4M FY24: 81.5M FY25: 97.3M FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Operating Income Annual

-150M -100M -50M 0 50M 100M 150M FY16: 798K FY17: -19.9M FY18: -77.2M FY19: -109.5M FY20: -126.7M FY21: -92.3M FY22: -79M FY23: -65.5M FY24: -96.8M FY25: -124.9M FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Net Income Annual

-180M -120M -60M 0 60M 120M 180M FY16: -1.9M FY17: -20M FY18: -75.7M FY19: -105.1M FY20: -128.5M FY21: -110.8M FY22: -109.8M FY23: -102.2M FY24: -126.9M FY25: -153.5M FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Cost of Revenue Annual

0 5M 10M 15M FY16: 28K FY17: 600K FY18: 1.8M FY20: 1M FY21: 5.2M FY22: 7.7M FY23: 9.4M FY24: 8.9M FY25: 12.4M FY16 FY17 FY18 FY20 FY21 FY22 FY23 FY24 FY25

Operating Cash Flow Annual

-180M -120M -60M 0 60M 120M 180M FY16: 4.2M FY17: -9.6M FY18: -37.3M FY19: -71M FY20: -105.9M FY21: -84.9M FY22: -87.6M FY23: -76.4M FY24: -96.8M FY25: -162.4M FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Free Cash Flow Annual

-180M -120M -60M 0 60M 120M 180M FY16: 3.5M FY17: -9.8M FY18: -37.9M FY19: -71.3M FY20: -107.1M FY21: -85.6M FY22: -87.8M FY23: -76.6M FY24: -97.1M FY25: -162.7M FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Operating cash flow minus capital expenditure.

Shares Outstanding Annual

0 20M 40M 60M FY21: 22.3M FY22: 22.8M FY23: 28.8M FY24: 42.9M FY25: 48.1M FY21 FY22 FY23 FY24 FY25

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-7.50 -5.00 -2.50 0.00 2.50 5.00 7.50 Q4 '17: -3.20 Q1 '18: -0.58 Q2 '18: -1.02 Q3 '18: -2.28 Q4 '18: -3.00 Q1 '19: -2.77 Q2 '19: -2.71 Q3 '19: -2.49 Q4 '19: -2.89 Q1 '20: -5.79 Q2 '20: -6.15 Q3 '20: -6.40 Q4 '20: -5.92 Q1 '21: -5.30 Q2 '21: -5.03 Q3 '21: -5.07 Q4 '21: -4.96 Q1 '22: -5.04 Q2 '22: -5.05 Q3 '22: -4.83 Q4 '22: -4.81 Q1 '23: -4.86 Q2 '23: -4.71 Q3 '23: -4.26 Q4 '23: -3.73 Q1 '24: -3.30 Q2 '24: -3.09 Q3 '24: -2.92 Q4 '24: -3.00 Q1 '25: -3.05 Q2 '25: -3.28 Q3 '25: -3.46 Q4 '25: -3.19 Q1 '26: -2.74 Q2 '26: -1.97 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.